Meeting Coverage >

ADA

Investigational GLP-1 RA Cuts Heart, Renal Risk in Vulnerable Diabetes Patients

Exendin-4-based drug succeeded in cardiovascular outcomes trial

180-Day Continuous Glucose Monitor Shows Promise in Adults With Diabetes

Implantable Eversense system demonstrates accuracy in prospective study

Hospitalization Rates for New-Onset Type 2 Diabetes in Kids Took Off During Pandemic

"COVID-19 disrupted our lives in more ways than we realize"

Combo GIP/GLP-1 Drug Superior for HbA1c Reduction in T2D

40-week trial compared tirzepatide head-to-head with injectable semaglutide

Urine Marker Predicts Kidney Benefit With Trulicity

Secondary AWARD-7 analysis finds subgroup getting the most renal protection

Expert Panel Defines CGM Time-in-Range Targets

Seventy percent of readings should stay between 70-180 mg/dL, according to recommendations

SGLT-2 Inhibitors Tied to Lower All-Cause Mortality Risk

Head-to-head comparison with DPP-4 inhibitors also showed heart protection

'Artificial Pancreas' System Boosts In-Hospital T2D Control

Less time out of range, no increase in insulin or lows with fully-automated system

Early T2D Treatment in Youth Disappoints

Metformin, insulin didn't stop deterioration of beta-cells in adolescents with impaired glucose

Intensive Treatment Doesn't Cost More

Therapy aimed at treating all organ targets extends life

Farxiga Lowers HbA1c in Type 1 Diabetes

Weight loss also accompanied better glycemic control

Sotagliflozin Tx Tied to HbA1c Reductions in T1D

But instances of diabetic ketoacidosis are a concern, expert says

GLP-1 Drug Boosts T1D Control

A1c, glucose, weight, blood pressure all improved in randomized trial

Basal Insulin Doesn't Cut Hypoglycemia Risk Vs NPH in T2D

Similar hypoglycemia-related emergency department and hospital admissions

Dual-Hormone Artificial Pancreas Ups T1D Glucose Control

Rapid insulin plus pramlintide also reduced glucose variability

180-Day Implantable CGM Deemed Safe in T1D Patients

The system's accuracy stabilized with longer use, researchers reported

Closed-Loop T1D Systems Show Promise

Omnipod, Diabeloop systems offer better glucose control than conventional treatment

Severity of Mom's Diabetes May Up Autism Risk in Their Kids

But GDM diagnosed after 26 weeks' gestation not associated with excess risk versus no diabetes

ADA's 2018 Meeting Spotlight Latest Trials

One of anticipated includes pediatric outcomes of RISE trial

Nasal Glucagon Helps Hypoglycemia in Adults with T1D

Possible alternative to injectable recombinant glucagon

Committee Wants Diabetes Docs to Watch Their Language

Not the word police, but 'diabetic' and 'non-compliant' must go

ADA Policy on Photos, Videos, Twitter Sparks Controversy

Association asked meeting-goers to delete tweets of presentation slides

Metformin No Help for Atherosclerosis in T1D

Findings don't support metformin in long-standing type 1 diabetes

Gestational Diabetes in Mom May Accelerate Kid's Puberty

Effects of diabetic exposure varied by sex

Mixed Findings on High Birth Weight, CV Risk Factors

Some markers of cardiovascular health better with high birth weight

Jardiance Shows Renal Benefit in EMPA-REG

Diabetes drug linked to slowing of kidney disease progression

Biosimilar Insulin Glargine Matches Up With Lantus in Phase III

Merck's copycat has similar HbA1c effect in trial

Survey: Diabetics Get Little Sympathy at Work

Co-workers give more slack to colleagues with other conditions

More Promising Results for Bionic Pancreas

But studies are short-term and relatively small

What's New in Beta Cell Transplantation

Gene editing, stem cells raise new possibilities

LEADER Trial Leads the Pack at ADA

But meeting in New Orleans will also feature thousands of new papers

ADA: Glucagon Nasal Powder Effective for Kids

Device that shoots powder up nose safe and effective, finds study.

GI Problems Make T2D Patients Ditch GLP-1 Tx

But physicians underestimate role of gastrointestinal side effects